Results 41 to 50 of about 26,699 (253)
Cardiac Myosin Inhibition for Treatment of LVOT Obstruction in a Patient With Severe AS
JACC: Case ReportsAortic stenosis and obstructive hypertrophic cardiomyopathy are common conditions. When both are present in the same patient, the management can be challenging.
Ronald H. Wharton, MD +4 more
doaj +1 more source
Progress in New Therapies Targeting the Pathogenesis of Cardiomyopathywith Hypertrophic Phenotype
罕见病研究, 2023 Hypertrophic cardiomyopathy (HCM) is cardiomyopathy with a clinical phenotype of cardiac hypertrophy. The etiology includes genetically defective encoding sarcomeres, congenital metabolic diseases such as lysosomal storage diseases, systemic amyloidosis ...
LIU Yanbo, TIAN Zhuang, ZHANG Shuyang
doaj +1 more source
Cardiac myosin inhibitors in hypertrophic cardiomyopathy
Journal of Cardiovascular ImagingAbstract Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular ...
Lim, Jaehyun, Kim, Hyung-Kwan
openaire +2 more sources
Advanced Healthcare Materials, EarlyView.Our coaxial electrospinning system is capable of incorporating decellularized myocardial extracellular matrix in a core‐sheath configuration, creating nanofibrous scaffolds. These scaffolds, in turn, support the maintenance of functional cardiomyocytes adhered to the surface of these bioactive scaffolds.
Dhanusha N. Rajapakse +9 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in ...
Caroline J. Coats +35 more
doaj +1 more source
Microengineered Gradient Hydrogels for Mechanobiology
Advanced Healthcare Materials, EarlyView.Gradient hydrogels are used to mimic the mechanical heterogeneity in native tissues, offering powerful in vitro platforms to study cell‐material interactions in diverse pathophysiological contexts. Here, we present a comprehensive review of the design and experimental considerations for stiffness gradient hydrogels, discussing exemplary achievements ...
Shin Wei Chong +4 more
wiley +1 more source
Frontiers in Cardiovascular MedicineMavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM).
Daniel Seung Kim +92 more
doaj +1 more source
Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?
ESC Heart Failure, 2023 Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy have been going head‐to‐head for the past 20 years with similar outcomes and mortality rates, although contemporary myectomy seems to materialize its superiority ...
Alexandru Achim +5 more
doaj +1 more source
Advanced Science, EarlyView.ABSTRACT Genome‐wide association studies (GWAS) link the Tropomyosin 1 (Tpm1) locus to quantitative blood trait variation, but related mechanisms are unclear. Tpm1 encodes an actin‐binding protein that regulates actin filament diversity, cell adhesion, signaling, and actomyosin contractility.
Po‐Lun Kung +19 more
wiley +1 more source
eLife, 2013 microRNA-1 (miR-1) is an evolutionarily conserved, striated muscle-enriched miRNA. Most mammalian genomes contain two copies of miR-1, and in mice, deletion of a single locus, miR-1-2, causes incompletely penetrant lethality and subtle cardiac defects ...
Amy Heidersbach +7 more
doaj +1 more source